Tag: Robert J. Fox

Poster-Disease-modifying Therapy

Baseline MRI Predictors of Cognitive Processing Speed in Participants with Secondary Progressive Multiple Sclerosis from the Phase 3 Expand Study

Background: Siponimod showed beneficial effects on magnetic resonance imaging (MRI) lesion activity, total brain and gray matter (GM)...

Read More

Poster-Disease-modifying Therapy

Long-Term Efficacy and Safety of Siponimod in Active SPMS and Overall SPMS Populations: Expand Study Data up to 5 Years

Background: In the EXPAND Core study, siponimod significantly reduced the risk of 3-/6-months(m) confirmed disability progression...

Read More

Platform-Disease Management

Prevalence of Cannabis Use and Associated Factors Among People with Multiple Sclerosis: A 2020 NARCOMS Survey

Background: The North American Research Committee on Multiple Sclerosis (NARCOMS) registry is a voluntary, self-report registry for people...

Read More

Platform-Disease Management

COVID-19 in Neuromyelitis Optica Spectrum Disorders and Myelin Oligodendrocyte Glycoprotein Antibody Disease Patients in North America

Background: The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) raised...

Read More